AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15668285
Drug: 3-weekly irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-weekly irinotecan at a dose of 300/240 mg/m(2) day 1 and days 22 in combination with capecitabine 1000 mg/m(2) twice daily days 1-14 and days 22-35 every 6 weeks (arm B)
Trial: 2873010
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg lormetazepam
Trial: 7785682
Drug: Topical 0.125%
RxNorm normalized name: sodium hypochlorite topical 0.125% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.125% verapamil
Trial: 7785682
Drug: Topical 0.25%
RxNorm normalized name: permethrin topical 0.25% topical kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.25% verapamil
Trial: 25076
Drug: Flunitrazepam 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 0.01 mg kg‐1
Trial: 25076
Drug: Flunitrazepam 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 0.02 mg kg‐1
Trial: 25076
Drug: Diazepam 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.125 mg kg‐1
Trial: 25076
Drug: Flunitrazepam double
RxNorm normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam double dose
Trial: 25076
Drug: Flunitrazepam larger
RxNorm normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam larger doses
Trial: 25076
Drug: Diazepam larger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam larger doses
Trial: 27900446
Drug: Obinutuzumab plus
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab plus bendamustine (G-B)
Trial: 23271192
Drug: Aripiprazole 2
RxNorm normalized name: aripiprazole 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 2 mg
Trial: 23271192
Drug: Aripiprazole 5
RxNorm normalized name: aripiprazole 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 5 mg
Trial: 18261195
Drug: Aripiprazole 10
RxNorm normalized name: aripiprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 10 mg
Trial: 23271192
Drug: Aripiprazole 30
RxNorm normalized name: aripiprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 30 mg
Trial: 19797985
Drug: Aripiprazole (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (all doses)
Trial: 20957705
Drug: Orlistat with
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat with cognitive‐behavioral therapy, guided‐self‐help (CBTgsh)
Trial: 19609438
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) as regular therapy
Trial: 15133343
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (three times every 3 hours)
Trial: 11358560
Drug: Ointment base
RxNorm normalized name: Ointment base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment base alone
Trial: 8024677
Drug: Mecamylamine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mecamylamine (various doses)
Trial: 22371898
Drug: Lersivirine (LRV)
RxNorm normalized name: ethanol
DrugBank: Lersivirine (DB11649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lersivirine (LRV) 2,400 mg
Trial: 17355729
Drug: Verteporfin photodynamic
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin photodynamic therapy combined with anti-angiogenic agents (ranibizumab or pegaptanib)
Trial: 17355729
Drug: Anti-angiogenic agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-angiogenic agents (ranibizumab or pegaptanib)
Trial: 19948277
Drug: Verteporfin photodynamic
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Verteporfin photodynamic therapy
Trial: 17355729
Drug: Anti-angiogenic agents
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-angiogenic agents
Trial: 16222916
Drug: Water fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water fortified with 10 mg elemental iron and 100 mg ascorbic acid per liter
Trial: 16222916
Drug: Water containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water containing only 100 mg ascorbic acid per liter
Trial: 7484997
Drug: Mesalazine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine (1.5 g/day) for 12 weeks after surgery
Trial: 2049250
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein meal (10.5 g of protein)
Trial: 2049250
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein meal (30.5 g of protein)
Trial: 7451775
Drug: Venom skin
RxNorm normalized name: MENTHA PIPERITA LEAF 10 g in 100 g / APIS MELLIFERA VENOM 30 g in 100 g / TOCOPHEROL 15 g in 100 g TOPICAL CREAM [HOUKEA Bee Venom Skin Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venom skin testing at concentrations of 1 microgram/ml or less
Trial: 6299612
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (Propranolol and Atenolol)
Trial: 29478874
Drug: Memory-Focused Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memory-Focused Cognitive Therapy (MFCT) sessions (5×120min in 1 week)
Trial: 29478874
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (ongoing treatment-as-usual; TAU)
Trial: 24568566
Drug: Male who
RxNorm normalized name: EQUISETUM HYEMALE WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Male who used a stimulant to study
Trial: 24568566
Drug: Nonmedical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmedical use of prescription stimulants (NMUPS) as a study aid
Trial: 17363405
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl PCA
Trial: 12592266
Drug: Control (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (after treatment)
Trial: 7041831
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg levamisole
Trial: 7041831
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg levamisole
Trial: 7041831
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg levamisole (classical dosage schedule)
Trial: 28321001
Drug: ARB/CCB combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB/CCB combination therapy (irbesartan 100 mg + amlodipine 5 mg)
Trial: 28321001
Drug: ARB/diuretic combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB/diuretic combination (daily irbesartan 100 mg + trichlormethiazide 1 mg)
Trial: 26445302
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) administered orally for 48 hours before and 24 hours after coronary angiography
Trial: 23644107
Drug: Syndrome differentiation-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syndrome differentiation-based treatment with traditional Chinese medicine (TCM)
Trial: 23644107
Drug: Oral losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral losartan therapy (50 mg/day)
Trial: 19428297
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of casopitant mesylate (150 mg)
Trial: 19428297
Drug: 3-day intravenous
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day intravenous plus oral casopitant mesylate (90 mg intravenous on day 1 plus 50 mg oral on days 2 and 3)
Trial: 17021784
Drug: Ear drops
RxNorm normalized name: Ear Drops
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ear drops containing antibiotic and corticosteroid (Control)
Trial: 10524688
Drug: Weekly MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly MTX
Trial: 1937373
Drug: 50% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% glucose in water (G/W)
Trial: 1937373
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (N/S)
Trial: 6129185
Drug: Insulin +
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin + cyclic SRIF (100 micrograms/hr i.v.) for ten hours
Trial: 6129185
Drug: Insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin alone (10 units as a bolus + infusion 1 U/hr)
Trial: 20437554
Drug: GKI infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GKI infusion
Trial: 18768029
Drug: Dental hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental hygiene activities including prophylaxis, sealants application, topical fluoride, fluoride mouthrinses, and tooth brushing instructional activity.
Trial: 15842138
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western medical treatment (Control)
Trial: 12578487
Drug: Acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (600 mg twice per day)
Trial: 8776276
Drug: Isradipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5 mg 3 times daily)
Trial: 15797966
Drug: DHEA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (50 mg/d, 16 wk)
Trial: 10326324
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cyclosporin A
Trial: 10326324
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cyclosporin A
Trial: 8567042
Drug: Remikiren (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren (600 mg, single oral dose) during high sodium period
Trial: 3554643
Drug: Cyclosporine (15‐17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (15‐17 mg/kg/day)
Trial: 3554643
Drug: Cyclosporine (15‐17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (15‐17 mg/kg/day) + Prednisolone (0.3 mg/kg/day)
Trial: 27177100
Drug: Heart‐Gallbladder acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart‐Gallbladder acupuncture treatment
Trial: 23286297
Drug: Conventional acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional acupuncture treatment
Trial: 22925832
Drug: Exercise (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise (both doses)
Trial: 9474071
Drug: Discontinuing hospital-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuing hospital-based treatment within 24 hours without achieving a peak expiratory flow rate of at least 50% of predicted
Trial: 2544254
Drug: Peripheral parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral parenteral nutrition (PPN) plus enteral nutrition (EN)
Trial: 31659803
Drug: GB001 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB001 (30 mg) once daily for 28 days
Trial: 29868915
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of pure (‐)‐epicatechin
Trial: 21944980
Drug: End-range mobilization/scapular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-range mobilization/scapular mobilization treatment approach (EMSMTA)
Trial: 21944980
Drug: Standardized physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized physical therapy program (criteria-control group)
Trial: 15820454
Drug: Oral linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral linezolid
Trial: 10594478
Drug: Dipyridamole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (200 mg) plus Acetylsalicylic Acid (25 mg)
Trial: 1978472
Drug: Remoxipride (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride (mean daily dose 437 mg)
Trial: 1978472
Drug: Haloperidol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (mean daily dose 10.6 mg)
Trial: 104084
Drug: Trifluorothymidine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluorothymidine (5 drops daily)
Trial: 31915048
Drug: 1 week
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 week of antibiotic therapy for residual osteomyelitis
Trial: 31915048
Drug: 3 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weeks of antibiotic therapy for residual osteomyelitis
Trial: 31915048
Drug: 1 day
RxNorm normalized name: ZonaCort 11 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 day of antibiotic therapy for remaining soft tissue infection
Trial: 31915048
Drug: 4 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 days of antibiotic therapy for remaining soft tissue infection
Trial: 31915048
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of antibiotic therapy for soft tissue infections
Trial: 31915048
Drug: 20 days
RxNorm normalized name: ferrous fumarate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 days of antibiotic therapy for soft tissue infections
Trial: 31915048
Drug: 3 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weeks of antibiotic therapy for osteomyelitis
Trial: 31915048
Drug: 6 weeks
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 weeks of antibiotic therapy for osteomyelitis
Trial: 22204724
Drug: Bevacizumab initiation
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab initiation (chemotherapy with bevacizumab added in cycles 2 through 6 and placebo in cycles 7 through 22)
Trial: 22204724
Drug: Bevacizumab throughout
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab throughout (chemotherapy with bevacizumab added in cycles 2 through 22)
Trial: 22204724
Drug: Control (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (chemotherapy with placebo added in cycles 2 through 22)
Trial: 22204724
Drug: Control (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (chemotherapy with placebo)
Trial: 19367154
Drug: HSV suppressive
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSV suppressive therapy for 4-6 years
Trial: 18593294
Drug: HSV suppressive
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSV suppressive therapy
Trial: 17323789
Drug: Fingolimod 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 1.25 mg single dose
Trial: 17323789
Drug: Fingolimod 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 2.5 mg single dose
Trial: 17323789
Drug: Fingolimod 5
RxNorm normalized name: fingolimod 500 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 5 mg single dose
Trial: 17323789
Drug: Fingolimod 5
RxNorm normalized name: fingolimod 500 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 5 mg/day for 7 days
Trial: 17323789
Drug: Fingolimod multiple-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod multiple-dose administration
Trial: 17323789
Drug: Fingolimod single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod single and multiple doses
Trial: 17323789
Drug: Fingolimod 5
RxNorm normalized name: fingolimod 500 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 5 mg/day multiple dose
Trial: 3198303
Drug: Atenolol plus
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol plus nifedipine (10 mg t.i.d.)
Trial: 477047
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg 3H‐digoxin intravenously and 0.125 mg orally as an alcoholic solution
Trial: 477047
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg unlabelled digoxin intravenously or a digoxin tablet
Trial: 30717153
Drug: DW2009 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DW2009 (800 mg/day)
Trial: 30717153
Drug: Placebo (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (800 mg/day)
Trial: 25961136
Drug: Daily TPTD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily TPTD for 24 months
Trial: 25961136
Drug: Daily TPTD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily TPTD for 24 months in ALN-Rx women
Trial: 22613418
Drug: 0.9% normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline infusion during spinal surgery (group SN)
Trial: 19906909
Drug: 3.5 microg
RxNorm normalized name: neomycin sulfate 3.5 MICROGRAM In 1 GRAM / polymyxin B sulfate 10000 UNITS In 1 GRAM / bacitracin zinc 400 UNITS In 1 GRAM OPHTHALMIC OINTMENT [Neosporin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 microg of the H5N1 vaccine (one or two doses)
Trial: 19906909
Drug: 6 microg
RxNorm normalized name: Zotarolimus 1.6 microgram/mm2 drug eluting stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 microg of the H5N1 vaccine (single dose)
Trial: 19906909
Drug: 12 microg
RxNorm normalized name: Levothyroxine sodium 112 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 microg of the H5N1 vaccine (single dose)
Trial: 19906909
Drug: 3.5 microg
RxNorm normalized name: neomycin sulfate 3.5 MICROGRAM In 1 GRAM / polymyxin B sulfate 10000 UNITS In 1 GRAM / bacitracin zinc 400 UNITS In 1 GRAM OPHTHALMIC OINTMENT [Neosporin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 microg of the H5N1 vaccine (one injection)
Trial: 19906909
Drug: 3.5 microg
RxNorm normalized name: neomycin sulfate 3.5 MICROGRAM In 1 GRAM / polymyxin B sulfate 10000 UNITS In 1 GRAM / bacitracin zinc 400 UNITS In 1 GRAM OPHTHALMIC OINTMENT [Neosporin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 microg of the H5N1 vaccine
Trial: 17914516
Drug: Topical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical mitomycin C (MMC) 0.4 mg/mL for 4 minutes
Trial: 16275598
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three drugs (Desipramine, Amitriptyline, Fluoxetine)
Trial: 11861354
Drug: inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled nitric oxide (iNO) 10 ppm in 100% oxygen
Trial: 535856
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (specific types not mentioned)
Trial: 535856
Drug: Two oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two oral contraceptives (different in dosage)
Trial: 23988507
Drug: High-dose-rate (HDR)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose-rate (HDR) brachytherapy (BT) boost after external beam irradiation (mean dose 62 Gy, range 50-70 Gy)
Trial: 16340517
Drug: Free nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Free nicotine replacement therapy (NRT) voucher
Trial: 11403336
Drug: Hydroxychloroquine 200
RxNorm normalized name: hydroxychloroquine 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 200 mg twice daily for 11 weeks
Trial: 11403336
Drug: Hydroxychloroquine 200
RxNorm normalized name: hydroxychloroquine 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 200 mg twice daily plus colchicine 0.6 mg twice daily for 12 weeks
Trial: 3312552
Drug: Indomethacin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.2 mg/kg intravenously, 24 hours after birth)
Trial: 27015752
Drug: Biological fixation
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological fixation (indirect reduction)
Trial: 23579888
Drug: hemostatic agent‐contaminated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hemostatic agent‐contaminated and rinsing with water
Trial: 23579888
Drug: hemostatic agent‐contaminated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hemostatic agent‐contaminated and ethylene diamine tetraacetic acid (EDTA) application
Trial: 23579888
Drug: hemostatic agent‐contaminated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hemostatic agent‐contaminated and phosphoric acid application
Trial: 20826420
Drug: Kinesiotaping combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesiotaping combined with botulinum toxin A (BTX‐A) injection
Trial: 20826420
Drug: Sham-taping combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-taping combined with botulinum toxin A (BTX‐A) injection
Trial: 7723357
Drug: Isomazole 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomazole 5 mg
Trial: 7723357
Drug: Isomazole 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomazole 10 mg
Trial: 7723357
Drug: Isomazole 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomazole 20 mg